(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 54.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.9%.
Ars Pharmaceuticals's revenue in 2025 is $97,122,000.On average, 3 Wall Street analysts forecast SPRY's revenue for 2025 to be $8,382,134,577, with the lowest SPRY revenue forecast at $7,312,981,752, and the highest SPRY revenue forecast at $9,259,574,531. On average, 4 Wall Street analysts forecast SPRY's revenue for 2026 to be $20,611,097,911, with the lowest SPRY revenue forecast at $12,476,068,654, and the highest SPRY revenue forecast at $24,397,230,688.
In 2027, SPRY is forecast to generate $36,118,331,698 in revenue, with the lowest revenue forecast at $30,794,862,052 and the highest revenue forecast at $40,493,451,200.